The government had cleared a Rs 5,168 crore proposal of US-based pharma firm Mylan Inc's to acquire Indian generic drugs company Agila Spec...

FIPB will take up tomorrow GlaxoSmithKline's Rs 6,400 crore FDI plan, the largest foreign investment proposal in the pharma sector this fis...

FDI in drugs and pharmaceuticals was at $580 million during April-October 2012, according to the data of the Department of Industrial Polic...

Currently, 100 per cent FDI is permitted in brownfield pharma firms through clearance from the Foreign Investment Promotion Board (FIPB).

The decision on FDI in pharma and housing has been deferred, Information and Broadcasting Minister Manish Tewari said after the Cabinet mee...

The Cabinet would also deliberate on the stand to be taken by India in the forthcoming WTO meet in Bali between December 3-6.

The Ministry of Commerce and Industry has proposed tighter overseas investment norms in existing drug companies by limiting all forms of fo...

DIPP has proposed to reduce FDI cap from 100 per cent to 49 per cent in the "rare or critical pharma verticals".

Faced with rush of multinationals to acquire Indian pharma firms, the Commerce and Industry Ministry is proposing to tighten the FDI policy...

The total investment as per the condition proposed would have to incurred within 3 years of the acquisition, they said.

The Planning Commission has opposed a proposal by DIPP to limit foreign direct investment in companies making ‘critical drugs’ to 49%.

Chidambaram today said the government will soon finalise the foreign investment policy on brownfield pharmaceutical projects.

DIPP, the nodal body for framing FDI policy, wants to review the policy to ensure there are enough safeguards to ensure domestic healthcare...

The FIPB discussed 30 Foreign Direct Investment (FDI) proposals, including 10 from pharma sector.

The government is likely to finalise FDI policy with regard to existing drug companies ahead of the FIPB meeting on July 5.

Nodal body for FDI policy DIPP to issue clarifications, paving the way for FIPB to take up pending proposals of Pfizer, B Braun & Sutures I...

The immediate trigger for the move was the acquisition of Ahmedabad-based Paras Pharmaceuticals by British consumer goods and healthcare fi...